Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY – Get Free Report)’s stock price gapped up prior to trading on Thursday . The stock had previously closed at $11.22, but opened at $11.80. Santen Pharmaceutical shares last traded at $11.72, with a volume of 15,270 shares trading hands.
Wall Street Analyst Weigh In
Separately, Zacks Research raised Santen Pharmaceutical to a “hold” rating in a research note on Monday, April 13th. One research analyst has rated the stock with a Hold rating, According to data from MarketBeat, Santen Pharmaceutical presently has a consensus rating of “Hold”.
Get Our Latest Stock Report on Santen Pharmaceutical
Santen Pharmaceutical Stock Performance
Santen Pharmaceutical Company Profile
Santen Pharmaceutical Co, Ltd. is a Japan?based specialty pharmaceutical company focused exclusively on ophthalmology. Headquartered in Osaka, Santen engages in the research, development, manufacture and marketing of prescription and over?the?counter products for the diagnosis and treatment of eye diseases. Its core product portfolio includes therapies for glaucoma, dry eye, retinal disorders, uveitis and post?operative care, as well as surgical equipment and diagnostic agents designed to support comprehensive eye care.
With roots tracing back to the late 19th century, Santen has grown from a domestic manufacturer to a global ophthalmic specialist.
Further Reading
- Five stocks we like better than Santen Pharmaceutical
- GitLab’s Price Recovery Gains Traction—Time to Get On Board?
- Rocket Lab Is Down 24% From Its 52-Week High—Pullback or Problem?
- The Blue Origin Explosion Is a Setback for Amazon, Not a Dealbreaker
- Before the IPO: 4 Companies That Rewarded Investors Who Got In Early
Receive News & Ratings for Santen Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Santen Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
